Last reviewed · How we verify
ceftazidime avibactam group (ceftazidime-avibactam-group)
At a glance
| Generic name | ceftazidime-avibactam-group |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Non-Interventional Study |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Approved indications
Pipeline indications
- Hospital Acquired Pneumonia — discontinued
Common side effects
Key clinical trials
- Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE2)
- Effect of Ceftazidime-Avibactam on Carbapenemase-Producing Klebsiella Pneumoniae
- Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales
- Real-World Study of Ceftazidime Avibactam in China
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients
- Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection (NA)
- A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ceftazidime avibactam group CI brief — competitive landscape report
- ceftazidime avibactam group updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI